Angela Keightley

Angela Keightley, PhD, has extensive work experience in the fields of assay development, genetic toxicology, immunology, and medicine. Angela is currently serving as the Vice President of Assay Development at BlueRock Therapeutics, a company focused on pioneering cell therapies for degenerative diseases. Prior to this role, they held positions at BlueRock as Senior Director and Director of Assay Development. Angela has also worked as the Director of Genetic Toxicology at Nucro-Technics Inc. and held various roles at Charles River Laboratories, including Principal Scientist, Senior Research Scientist, Research Scientist, and Scientist, specializing in immunology and genetic toxicology. Angela started their career as a Post-Doctoral Fellow at the University of Toronto in the Department of Medicine.

Angela Keightley, PhD, completed their Honours Bachelor of Science (HBSc) degree in Biology/Biological Sciences from Trent University between 1989 and 1993. Angela then pursued their Ph.D. in Pathology, Molecular Genetics at Queen's University from 1994 to 2000.